Studying a hormone in the venom of this reptile species that may allow it to eat infrequently led to the weight-loss drug Ozempic
On the March 9, 2026 episode of Jeopardy!, the Final Jeopardy category was “Reptiles.” Contestants were presented with a clue that connected reptile biology to modern medicine and one of the most widely discussed pharmaceutical treatments for diabetes and weight loss.
The clue read: “Studying a hormone in the venom of this reptile species that may allow it to eat infrequently led to the weight-loss drug Ozempic.” The question required knowledge not only of reptile species but also of how biological research can lead to important medical discoveries. The correct response pointed to a desert reptile whose venom contains a hormone that helped inspire a breakthrough class of medications used to regulate blood sugar and appetite.
Contents
What is the Gila Monster?
The Gila monster (Heloderma suspectum) is a venomous lizard native to the southwestern United States and northwestern Mexico. It is one of only a few venomous lizard species known to science. Recognizable for its distinctive orange-and-black patterned skin, the Gila monster inhabits arid desert environments and spends much of its life underground in burrows to escape extreme heat.
What made this species particularly important to medical researchers is a hormone found in its venom called exendin-4. Scientists studying the Gila monster discovered that this hormone behaves similarly to a human hormone involved in regulating blood sugar and appetite. Because the lizard often eats large meals but then goes long periods without food, researchers believed this compound might play a role in controlling metabolism.
The Biological Discovery Behind Ozempic
Exendin-4 attracted attention because it closely mimics GLP-1 (glucagon-like peptide-1), a hormone produced in the human gut. GLP-1 helps regulate blood sugar levels by stimulating insulin release, slowing stomach emptying, and increasing feelings of fullness after eating. However, the human version of GLP-1 breaks down quickly in the body.
The version found in the Gila monster’s venom proved far more stable. This discovery allowed researchers to develop medications that mimic the hormone’s effects but remain active in the body longer. One of the earliest drugs derived from this research was exenatide, approved in 2005 for the treatment of type 2 diabetes.
From Venom Research to Modern Weight-Loss Treatments
The scientific work on exendin-4 helped launch a broader class of medications known as GLP-1 receptor agonists. These drugs improve blood sugar control and also reduce appetite, which can lead to significant weight loss. Over time, pharmaceutical development led to newer and longer-acting versions of these medications.
Ozempic (semaglutide) is one of the most prominent drugs in this category. Originally approved to treat type 2 diabetes, it later gained attention for its effectiveness in supporting weight loss by helping regulate appetite and slowing digestion. Although Ozempic itself is not directly made from Gila monster venom, the original discovery of exendin-4 provided the scientific foundation that made this class of drugs possible.
The Gila Monster’s Place in Science and Medicine
The story behind this Final Jeopardy clue highlights how studying unusual biological systems can lead to important medical breakthroughs. Research into the feeding patterns and venom chemistry of the Gila monster revealed mechanisms that could be applied to human metabolism and disease treatment.
Today, the Gila monster remains an important example of how wildlife research contributes to advances in biotechnology and pharmacology. What began as a study of a desert reptile’s venom ultimately helped inspire therapies that now play a major role in the treatment of diabetes and obesity worldwide.
